Antibiotice Sa · BVB:ATB
Antibiotice Sa — Investor Presentation (October 2020)
38 slides from Antibiotice Sa's investor presentation, October 2020
Slide 1: Antibiotice, a first-rank company in the relationship with its investors
Antibiotice, a first-rank company in the relationship with its investors* Presentation for investors October 2020 *According to the VEKTOR indicator of the Romanian Investors Relations Association(ARIR)
Slide 2: Disclaimer
Disclaimer Write it here This presentation does not constitute and should not be construed as representing or being part of any current offer to sell or issue shares, or as a purchase or subscription request for any shares issued by Antibiotice S.A. No part of this presentation may be invoked in con
Slide 3: Contents
Contents Write it here Company profile Development strategy H I 2020: activity and results 3
Slide 4: Company Profile
Company Profile E Antibiotice ot ees since 1955
Slide 5: Antibiotice in brief
Antibiotice in brief Write it here Antibiotice today Mission The main manufacturer of generic anti- infective medicines in Romania. We make our valuable medicines more accessible to patients, World leader in production of the active physicians and pharmacists. We substance Nystatin: 65% which is a U
Slide 6: Leader in an attractive market
Leader in an attractive market Write it here Domestic position and market share Performance in the external market • Leader in the antiinfectives #1 class in the generic category (31.06% market share) 40% • Leader in the hospital #1 segment, RX and OTC of turnover represents medicines (15.6%) export
Slide 7: A company with a rich tradition
A company with a rich tradition Write it here 1955-1990 - The first 1990-2000 manufacturer of - Antibiotice 2000-2010 penicillin in Romania and becomes a joint 2010-2015 South-East stock company -Modernization Europe - Listing on the investments -Increased 2015-2020 Stock Exchange - FDA exports Buch
Slide 8: Financial performance
Financial performance Write it here Turnover Export Profit million LEI million LEI million LEI 450 180 40 391 153 35 35 400 365 160 35 32 331 140 350 30 124 300 120 243.6 25 250 100 92.7 20 18 200 80 57.1 15 150 60 100 40 10 50 20 5 0 0 0 2010 2015 2018 2019 2010 2015 2018 2019 2010 2015 2018 2019 A
Slide 9: Antibiotice, a responsible company
Write it here Antibiotice, a responsible company • Blood donation • „Science and Soul” campaigns Scholarships, a • First aid courses for program to support our employees the children in rural areas Health Education Social Environment • Social programs • Programs for through the protecting the „Antib
Slide 10: Shareholding
Shareholding Write it here La data de 30.06.2020 10
Slide 11: Development strategy
Development strategy . Antibiotice GAZ eit he since 1955
Slide 12: Strategic development pillars
Strategic development pillars Write it here Internationalization of our business and Strategic Investments – the Adapting human Integrated Quality its consolidation in adaptation of our guarantee of the resources to Management the domestic portfolio future strategic directions market + Quick adaptin
Slide 13: Evolution of the main economic-financial indicators
Write it here Evolution of the main economic-financial indicators No. Indicators 2000 2005 2010 2015 2020 – valori estimate 1. Turnover(mil. LEI), of which: 62,2 163,5 243,6 331,7 377,7 2. Export sales (mil. LEI) 12,1 20,4 57,1 92,7 158,0 3. Operating income(mil. LEI) 61,9 164,8 248,5 342,1 394,3 4.
Slide 14: Evolution of the main economic-financial indicators (continued)
Write it here No. Indicators 2000 2005 2010 2015 2020 – estimated values 10. Gross profitability 9,5% 14,5% 7,6% 9,6% 6,5% 11. Fixed assets (mil. LEI) 38,9 85,6 168,4 195,5 389,7 12. Current assets (mil. LEI) 38,4 126,2 223,9 327,3 436,0 13. Total assets (mil. LEI) 77,5 211,8 392,7 524,5 825,7 14. T
Slide 15: Responsibility, Cooperation and Partnerships
Write it here Responsibility, Cooperation and Partnerships - Analysis, evaluation and limitation of expenses corroborated with achieved revenues and urgent needs; - Balance of financial flows of receipts and payments, on each currency to limit financial expenses; - Sustained investments for future d
Slide 16: Internationalization of our business and its consolidation in the domestic market
Internationalization of our business and its Write it here consolidation in the domestic market Nystatin, Strategic objectives active substance - 50 strengthening our world leadership position internationally 4 Increasing product sales in both registered products Antibiotice and assimilated territor
Slide 17: Strengthening the internal market
Strengthening the internal market Strategic objectives • Strengthening the leading position on the hospital #1 segment by adapting our portfolio and commercial policies GRO SS TURN O V ER – IN TERN A L MA RKET (MIL L EI) • Strengthening the leading position on the Anti- #1 infectives class – generic
Slide 18: Strategic adaptation of our portfolio
Write Write itit here here Strategic adaptation of our portfolio Strategic objectives Therapeutic areas Increasing sales in the hospital portfolio Injectable and oral antiinfectives Increasing the production capacity of Topical medicines topicals 150 Nutriensa Development of new products in all Prod
Slide 19: Investments – the guarantee of the future
Investments – the guarantee of the future Write it here Building a new manufacturing plant for ointments and suppositories 20 mil EUR Building a new manufacturing plant for sterile solutions 60 mil EUR Upgrading, diversifying the assortment range and increasing the capacity for 10 mil EUR manufactur
Slide 20: Adapting human resources to the company’s strategic directions
Write it here Adapting human resources to the company’s strategic directions Strategic objectives Qualified personnel Supporting professional Balanced staff 1,415 structure development employees 45% Improving Increasing our organizational employees’ Specialists with climate motivation higher educati
Slide 21: Integrated quality management
Write it here Integrated quality management Integrated quality management system (quality, environment, occupational health and safety) International quality certifications: • EU-GMP for 8 manufacturing flows; Objective: • US - FDA for sterile injectable powders Supporting the and Nystatin API; busi
Slide 22: Rapid adaptation to the extraordinary pandemic situation
Write it here Rapid adaptation to the extraordinary pandemic situation State of emergency Strategic objectives ATB crisis cell Supporting the Romanian medical • Reducing indirectly productive system with medicines of strict Scenario 1 activities, work from home necessity, during the pandemic • compl
Slide 23: Effective protection measures in a crisis situation
Effective protection measures in a crisis situation State of alert Adopted measures H I 2020 results • Measures for protecting our employees - Protection outfits & disinfectants - Monitoring the state of health through periodic medical controls - Testing the personnel (PCR/quick tests) upon 0 Corona
Slide 24: Performance indicators for the executive team
Write it here Performance indicators for the executive team INDICATORS for EXECUTIVE ADMINISTRATORS Weighting 2020 Sales revenues (mil. LEI) 10% 376,96 Gross profit (mil. LEI) 15% 24,50 Arrears (mil. LEI) 15% 0 Total expenses per 1000 lei income 10% 939 Degree of utilization of production capacity n
Slide 25: Semester I 2020: activity and results
Semester I 2020: activity and results
Slide 26: Achievements in the first semester of 2020
Write it here Achievements in the first semester of 2020 146.4 million LEI Maintaining the position Adapting the production registered revenues, of of world market leader to the extraordinary which 50% export for the active substance pandemic situation revenues Nystatin Effective protection Maintain
Slide 27: Revenues achieved according to market dynamics
Write it here Revenues achieved according to market dynamics Market dynamics Results Revenues (million LEI) • Dynamics of the pharmaceutical market was affected by the pandemic 72.6, 50% 73.8, 50% • The demand for anti-infectives associated with the Covid-19 Export Piața internă treatment increased.
Slide 28: Strategic adaptation of our portfolio
Strategic adaptation of our portfolio Write it here Achivements A new manufacturing structure • Reintroducing into manufacturing the medicines Paracetamol and Novocalmin for Covid-19; Oral Solids •integrates the activities of the Capsule Plant and Division Tablet Plant • Speeding the research-develo
Slide 29: Continuation of the investment program for the future
Write it here Continuation of the investment program for the future Investments amounting to 25.97 million LEI, of the total amount of 78.91 million LEI for the investment program 2020 Investments (million LEI) 4.99 4.23 4.12 1.51 10.92 0.2 cercetare-dezvoltare noi site-uri de producție site-uri de
Slide 30: Effective protection measures in a crisis situation
Effective protection measures in a crisis situation State of alert Adopted measures H I 2020 results • Measures for protecting our employees - Protection outfits & disinfectants - Monitoring the state of health through periodic medical controls - Testing the personnel (PCR/quick tests) upon 0 Corona
Slide 31: Balanced economic activity
Write it here Balanced economic activity Indicators 06.2020/ 30.06.2019 30.06.2020 06.2019 Sales income(mil. LEI) 172,4 146,4 0,85 Gross profir (mil. LEI) 24,9 19,4 0,78 Arrears (mil. LEI) 0 0 1,00 Total expenses to 1,000 LEI income 879 894 0,98 Maintaining a balanced evolution of income-expenditure
Slide 32: Comprehensive income statement
Comprehensive income statement Write it here Financial indicators (LEI) 30.06.2019 30.06.2020 30.06.2020/ 30.06.2019 Sales income 172.391.095 146.377.930 0,85 Other operating income 18.686.567 22.243.720 1,19 Revenues related to the costs of product stocks 26.243.033 26.727.927 1,02 Capitalized inco
Slide 33: Financial statement: assets
Financial statement: assets Write it here Financial indicators (LEI) 31.12.2019 30.06.2020 30.06.2020/ 31.12.2019 ASSETS FIXED ASSETS Tangible fixed assets 363.616.611 379.243.099 1,04 Intangible fixed assets 16.385.709 18.062.450 1,10 TOTAL FIXED ASSETS 380.002.320 397.305.549 1,05 CURRENT ASSETS S
Slide 34: Financial statement: liabilities
Financial statement: liabilities Write it here Financial indicators (lei) 31.12.2019 30.06.2020 30.06.2020 / 31.12.2019 LIABILITIES CURRENT LIABILITIES Trade and similar debts 72.337.840 79.450.266 1,10 Amounts owed to credit institutions 125.875.879 109.986.199 0,87 Debts from current taxes and fee
Slide 35: Financial statement: share capital and reserves
Financial statement: share capital and reserves Write it here Financial indicators (LEI) 31.12.2019 30.06.2020 30.06.2020/ 31.12.2019 Share capital and reserves Share capital 264.835.156 264.835.156 1,00 Revaluation reserves 50.804.319 49.499.028 0,97 Legal reserves 13.426.761 13.426.761 1,00 Other
Slide 36: ATB shares on the Stock Exchange
ATB shares on the Stock Exchange Write it here 10,404,214 shares, with a total value of 1,105,555 EUR were traded. 36
Slide 37: Conclusions
Conclusions Write it here Market leader in an attractive sector An ambitious and responsible development strategy Performance indicators in line with the strategy Quick adaptation to extraordinary situations A first ranked company in the relationship with the investors 37
Slide 38: www.antibiotice.ro
Contact pentru investor relations Website: www.antibiotice.ro/investitori-php/ Email: relatiicuinvestitorii@antibiotice.ro www.antibiotice.ro